Merck & Company Inc (MRK)vsOncology Institute Inc (TOI)
MRK
Merck & Company Inc
$112.16
+2.73%
HEALTHCARE · Cap: $274.03B
TOI
Oncology Institute Inc
$4.05
+4.92%
HEALTHCARE · Cap: $366.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 12832% more annual revenue ($65.01B vs $502.73M). MRK leads profitability with a 28.1% profit margin vs -12.1%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$112.16
$15.60 premium
Margin of Safety
+80.1%
Fair Value
$13.17
Current Price
$4.05
$9.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 41.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -652.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while TOI is a hypergrowth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
TOI is growing revenue faster at 41.6% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 45/100), backed by strong 28.1% margins. TOI offers better value entry with a 80.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a pioneering healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment modalities. The company prioritizes enhanced patient outcomes by leveraging state-of-the-art technologies and customized treatment plans, while also participating in clinical trials and collaborations with leading research institutions. As the need for advanced cancer therapies continues to grow, TOI is strategically positioned to leverage its robust pipeline and deep-seated oncology expertise, reinforcing its status as a key player in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?